HER2-positive Breast Cancer Clinical Trials in Shenyang, Liaoning
2 recruitingShenyang, Liaoning, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled77 locationsNCT07043725
Recruiting
Phase 2
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
HER2-positive Breast Cancer
Shengjing Hospital65 enrolled1 locationNCT05635487